TK1在肺癌诊断和预后判断中的研究进展  

Advances of thymidine kinase 1 in the diagnosis and prognosis of lung cancer

作　　者：宁莉莉[1] 王宇鹏[2] 余飞[1] 盛冠男 陈冠男[1] 屈波[1] 

机构地区：[1]武警后勤学院附属医院,天津300162 [2]天津市北辰医院,天津300400

出　　处：《现代肿瘤医学》2017年第7期1151-1155,共5页Journal of Modern Oncology

基　　金：国家自然科学基金面上项目(编号:81272547);武警后勤学院附属医院科研种子基金项目(编号:FYM201609)

摘　　要：肺癌是当今世界上最常见的恶性肿瘤之一。随着各种新型化疗药物及分子靶向药物的出现,肺癌的治疗手段不断增多,但由于缺乏有效的早期诊断方法以及预后评估指标,无法制定个体化的治疗方案,其预后仍不理想。胸苷激酶(TK1)是一种新近发现的国际公认的细胞增殖特异性标记物,其与传统的肿瘤标志物及CT结合能有效评估肿瘤放化疗疗效及预后,有助于指导肿瘤患者个体化治疗方案的制定。本文通过查阅国内外最新相关文献,拟对TK1和传统检测指标在肺癌预后评估方面的研究进展做一综述。Lung cancer（ LC） accounts for the majority of cancer worldwide currently. The treatment for LC has increased by the innovation of novel chemotherapeutic drugs and molecular targeted drugs. Because of the lack of early diagnostic measurement and prognostic markers,we can ＇t make an individualized plan for patient,the prognostic of lung cancer is still poor. Thymidine kinase 1 activity in serum（ STKa） is a new cell- proliferating marker that has been used for the prognosis and monitoring of treatment. The combine of TK1 and computerized tomographic scanning（ CT） contribute to the formulation of individualized treatment plan for cancer patient. This article tries to introduce the advances of Thymidine kinase 1 in the diagnostic and prognostic of lung cancer by reading the newly articles worldwide.

关 键 词：胸苷激酶 肺癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]